To ask the Secretary of State for Health and Social Care, what criteria is being used to prioritise clinically vulnerable, moderate risk, people with inflammatory bowel disease for the covid-19 vaccine; and which healthcare professionals are responsible for identifying those patients and adding them to the appropriate vaccination list.
13 April 2021
The Joint Committee on Vaccination and Immunisation current view is that inflammatory bowel disease is not in itself an indicator of increased risk of serious outcomes from COVID-19. However where an individual is, as a result of disease or treatment, immunosuppressed they may be either defined as clinically extremely vulnerable (CEV) and therefore are prioritised in priority group 4 in Phase 1 of the vaccine programme or if the immunosuppression is less severe will have been included in priority group 6. Clinicians responsible for individuals’ care, whether in hospital or in primary care, are primarily responsible for ensuring they are in the appropriate priority group. Anyone who is concerned that they have not been yet offered vaccination but believe they do meet the criteria for either group 4 or 6 may wish to discuss with their general practitioner or hospital clinician.